Recruiting
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT06616155· Phase 1/2· University of Michigan Rogel Cancer Center· Source
Contact: Cancer AnswerLine
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· Phase 1· Eli Lilly and Company· Source
Recruiting
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
NCT06914479· Phase 1· University of Michigan Rogel Cancer Center· Source
Contact: Andrea T. Franson
Recruiting
Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
NCT07158021· Phase 2· University of Michigan Rogel Cancer Center· Source
Contact: Cancer AnswerLine
Active, not recruiting
A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
NCT07291414· University of Michigan Rogel Cancer Center· Source
Recruiting
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
NCT07094685· Phase 2· University of Michigan Rogel Cancer Center· Source
Contact: Cancer AnswerLine
Recruiting
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
NCT07132645· Early phase 1· University of Michigan Rogel Cancer Center· Source
Contact: Benjamin Viglianti
Recruiting
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
NCT06866262· Phase 1/2· University of Michigan Rogel Cancer Center· Source
Contact: Ulka N. Vaishampayan
Recruiting
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
NCT06356155· Phase 2· University of Michigan Rogel Cancer Center· Source
Contact: Irene Tsung, M.D.
Recruiting
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
NCT07121595· Phase 2· University of Michigan Rogel Cancer Center· Source
Contact: Cancer AnswerLine
Recruiting
Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors
NCT06941324· University of Michigan Rogel Cancer Center· Source
Contact: Cancer AnswerLine
Active, not recruiting
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
NCT06580054· Phase 2· University of Michigan Rogel Cancer Center· Source
Recruiting
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
NCT07096999· University of Michigan Rogel Cancer Center· Source
Contact: James Pool
Recruiting
CIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer
NCT06915168· University of Michigan Rogel Cancer Center· Source
Contact: Daniel L. Hertz
Recruiting
Gilteritinib for the Treatment of ALK NSCLC
NCT06225427· Phase 1· University of Michigan Rogel Cancer Center· Source
Contact: Angel Qin
Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768· Phase 3· SWOG Cancer Research Network· Source
Contact: Erin F. Cobain (principal investigator)
Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT05735184· Phase 1· Kura Oncology, Inc.· Source
Contact: Cancer AnswerLine
Active, not recruiting
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602· Phase 3· SWOG Cancer Research Network· Source
Active, not recruiting
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
A Study of Daratumumab
NCT05438043· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response
NCT05610163· Phase 2/3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
NCT05241860· Phase 2· Alliance for Clinical Trials in Oncology· Source
Recruiting
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
NCT05168163· Phase 2· Academic and Community Cancer Research United· Source
Contact: Cindy Rekowski
Recruiting
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360· Phase 2· SWOG Cancer Research Network· Source
Contact: Vaibhav Sahai (principal investigator)
Active, not recruiting
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT05096663· Phase 2/3· SWOG Cancer Research Network· Source
Active, not recruiting
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT04647916· Phase 2· SWOG Cancer Research Network· Source
Active, not recruiting
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
NCT04662580· Phase 1· Janssen Research & Development, LLC· Source
Recruiting
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597· Phase 3· SWOG Cancer Research Network· Source
Contact: Ulka N. Vaishampayan (principal investigator)
Active, not recruiting
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer
NCT04559139· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source
Contact: EORTC HQ
Recruiting
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013· Phase 2· SWOG Cancer Research Network· Source
Contact: Christopher D. Lao (principal investigator)
Active, not recruiting
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541· Phase 1/2· Genmab· Source
Active, not recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
NCT04246086· Phase 1/2· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493· Phase 3· Epizyme, Inc.· Source
Active, not recruiting
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
NCT04164901· Phase 3· Institut de Recherches Internationales Servier· Source
Active, not recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· Phase 2/3· NRG Oncology· Source
Active, not recruiting
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT04115631· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients With Brain Metastasis That Has Been Removed by Surgery
NCT04114981· Phase 3· Alliance for Clinical Trials in Oncology· Source
Active, not recruiting
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
NCT03962543· Phase 2· SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany· Source
Active, not recruiting
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457· Phase 3· SWOG Cancer Research Network· Source
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025· Phase 3· SWOG Cancer Research Network· Source
Contact: Samuel D. Kaffenberger (principal investigator)
Recruiting
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
NCT03583710· Phase 3· M.D. Anderson Cancer Center· Source
Contact: Francis P. Worden
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796· Phase 2/3· Celgene· Source
Contact: Monalisa Ghosh, Site 01024
Active, not recruiting
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
NCT03308396· Phase 1/2· Ajjai Alva, MD· Source
Active, not recruiting
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
NCT03267433· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
NCT03331198· Phase 1/2· Juno Therapeutics, a Subsidiary of Celgene· Source
Recruiting
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
NCT03418961· Phase 3· SWOG Cancer Research Network· Source
Contact: Erin F. Cobain (principal investigator)
Active, not recruiting
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
NCT03091660· Phase 3· SWOG Cancer Research Network· Source
Showing 50 of 65.